| Title |
Drug Interactions Update: Drugs, Herbs, and Oral Anticoagulation
|
|---|---|
| Published in |
Journal of Thrombosis and Thrombolysis, September 2001
|
| DOI | 10.1023/a:1012742628628 |
| Pubmed ID | |
| Authors |
Ann K. Wittkowsky |
| Abstract |
Management of warfarin drug interactions is often complicated by lack of information regarding interactions with new drugs and with herbal medicinals. The pharmaceutical industry has increased both the number and quality of drug interaction studies prior to marketing new agents. Interactions may still occur in patients, however, despite negative pre-marketing studies in healthy volunteers. The clinical significance and intensity of warfarin interactions with prescription drugs (e.g., celecoxib, proton pump inhibitors, and selective serotonin reuptake inhibitors) can often be predicted on the basis of known metabolic characteristics of the drugs and warfarin enantiomers. Drug interactions with herbal medicinals are much more difficult to characterize and predict because of the lack of federal regulations regarding safety, efficacy, and manufacturing standards. Published case reports of interactions between warfarin and even the most widely used herbal medicinals are limited. Practitioners are encouraged to report such interactions through the FDA MedWatch program. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 6% |
| Colombia | 1 | 3% |
| Slovenia | 1 | 3% |
| Unknown | 31 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 23% |
| Student > Postgraduate | 5 | 14% |
| Student > Ph. D. Student | 4 | 11% |
| Student > Master | 4 | 11% |
| Other | 3 | 9% |
| Other | 4 | 11% |
| Unknown | 7 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 40% |
| Agricultural and Biological Sciences | 6 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 14% |
| Chemistry | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 7 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2022.
All research outputs
#8,533,995
of 25,371,288 outputs
Outputs from Journal of Thrombosis and Thrombolysis
#372
of 1,064 outputs
Outputs of similar age
#14,139
of 40,833 outputs
Outputs of similar age from Journal of Thrombosis and Thrombolysis
#1
of 3 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,064 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 40,833 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them